| First Author | Frankel AE | Year | 2016 |
| Journal | Cancer Discov | Volume | 6 |
| Issue | 9 | Pages | 949-52 |
| PubMed ID | 27587466 | Mgi Jnum | J:236869 |
| Mgi Id | MGI:5810025 | Doi | 10.1158/2159-8290.CD-16-0800 |
| Citation | Frankel AE, et al. (2016) Developing EZH2-Targeted Therapy for Lung Cancer. Cancer Discov 6(9):949-52 |
| abstractText | Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949-52. (c)2016 AACRSee related article by Zhang and colleagues, p. 1006. |
